Literature DB >> 33328707

Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases.

Carin F Gonsalves1, Robert D Adamo1, David J Eschelman1.   

Abstract

Uveal melanoma is the most common primary intraocular malignant tumor in adults. Approximately 50% of patients develop metastatic disease of which greater than 90% of patients develop hepatic metastases. Following the development of liver tumors, overall survival is dismal with hepatic failure being the cause of death in nearly all cases. To prolong survival for patients with metastatic uveal melanoma, controlling the growth of hepatic tumors is essential. This article will discuss imaging surveillance following the diagnosis of primary uveal melanoma; locoregional therapies used to control the growth of hepatic metastases including chemoembolization, immunoembolization, radioembolization, percutaneous hepatic perfusion, and thermal ablation; as well as currently available systemic treatment options for metastatic uveal melanoma. Thieme. All rights reserved.

Entities:  

Keywords:  chemoembolization; immunoembolization; percutaneous hepatic perfusion; radioembolization; uveal melanoma

Year:  2020        PMID: 33328707      PMCID: PMC7732575          DOI: 10.1055/s-0040-1720948

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  48 in total

1.  High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Authors:  Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

2.  Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Authors:  Markus V Heppt; Lucie Heinzerling; Katharina C Kähler; Andrea Forschner; Michael C Kirchberger; Carmen Loquai; Markus Meissner; Friedegund Meier; Patrick Terheyden; Beatrice Schell; Rudolf Herbst; Daniela Göppner; Felix Kiecker; David Rafei-Shamsabadi; Sebastian Haferkamp; Margit A Huber; Jochen Utikal; Mirjana Ziemer; Irmgard Bumeder; Christiane Pfeiffer; Susanne G Schäd; Christoph Schmid-Tannwald; Julia K Tietze; Thomas K Eigentler; Carola Berking
Journal:  Eur J Cancer       Date:  2017-06-22       Impact factor: 9.162

Review 3.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

Review 4.  Ocular melanoma: relatively rare but requiring respect.

Authors:  Carol L Shields; Jerry A Shields
Journal:  Clin Dermatol       Date:  2009 Jan-Feb       Impact factor: 3.541

5.  Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma.

Authors:  Anja Ulmer; Julia Beutel; Daniela Süsskind; Ralf-Dieter Hilgers; Focke Ziemssen; Matthias Lüke; Martin Röcken; Martin Rohrbach; Gerhard Fierlbeck; Karl-Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

6.  Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie.

Authors:  P Mariani; S Piperno-Neumann; V Servois; M G Berry; T Dorval; C Plancher; J Couturier; C Levy-Gabriel; L Lumbroso-Le Rouic; L Desjardins; R J Salmon
Journal:  Eur J Surg Oncol       Date:  2009-03-28       Impact factor: 4.424

7.  PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Authors:  Matthew G Field; Christina L Decatur; Stefan Kurtenbach; Gülçin Gezgin; Pieter A van der Velden; Martine J Jager; Kaleigh N Kozak; J William Harbour
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

8.  Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

Authors:  Giammaria Fiorentini; Camillo Aliberti; Alessandro Del Conte; Massimo Tilli; Susanna Rossi; Pierluigi Ballardini; Gina Turrisi; Giorgio Benea
Journal:  In Vivo       Date:  2009 Jan-Feb       Impact factor: 2.155

Review 9.  The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Authors:  Sung Wook Shin
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

10.  Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Authors:  Richard D Carvajal; Jeffrey A Sosman; Jorge Fernando Quevedo; Mohammed M Milhem; Anthony M Joshua; Ragini R Kudchadkar; Gerald P Linette; Thomas F Gajewski; Jose Lutzky; David H Lawson; Christopher D Lao; Patrick J Flynn; Mark R Albertini; Takami Sato; Karl Lewis; Austin Doyle; Kristin Ancell; Katherine S Panageas; Mark Bluth; Cyrus Hedvat; Joseph Erinjeri; Grazia Ambrosini; Brian Marr; David H Abramson; Mark Andrew Dickson; Jedd D Wolchok; Paul B Chapman; Gary K Schwartz
Journal:  JAMA       Date:  2014-06-18       Impact factor: 157.335

View more
  3 in total

1.  Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Authors:  Cornelia L A Dewald; Mia-Maria Warnke; Roland Brüning; Martin A Schneider; Peter Wohlmuth; Jan B Hinrichs; Anna Saborowski; Arndt Vogel; Frank K Wacker
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

2.  Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

Authors:  T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn
Journal:  Trials       Date:  2022-02-13       Impact factor: 2.279

3.  Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.

Authors:  T M L Tong; M Samim; E Kapiteijn; T S Meijer; F M Speetjens; R Brüning; T H Schroeder; S El-Sanosy; H Maschke; F K Wacker; A Vogel; C L A Dewald; J J Goeman; M C Burgmans
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-03       Impact factor: 2.797

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.